Tatsuki Ikoma, Toshihiko Matsumoto, Shogen Boku, Yusuke Motoki, Hidefumi Kinoshita, Hisashi Kosaka, Masaki Kaibori, Kentaro Inoue, Mitsugu Sekimoto, Takuo Fujisawa, Hiroshi Iwai, Makoto Naganuma, Hideaki Tanizaki, Yoji Hisamatsu, Hidetaka Okada, Takayasu Kurata
BACKGROUND: Immuno-oncology (IO) drugs are essential for treating various cancer types; however, safety concerns persist in older patients. Although the incidence of immune-related adverse events (irAEs) is similar among age groups, higher rates of hospitalization or discontinuation of IO therapy have been reported in older patients. Limited research exists on IO drug safety and risk factors in older adults. Our investigation aimed to assess the incidence of irAEs and identify the potential risk factors associated with their development...
May 11, 2024: Cancer Immunology, Immunotherapy: CII